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7 h; if the culture of a specimen of purulent drainage from the insertion site showed S. 82 auerus; or if clinical signs improved after the catheter was removed and there was no 83 other source for bacteremia. Pneumonia was considered to be the source of S. aureus 84 bacteremia if the patient had clinical symptoms and signs of a lower respiratory tract 85 infection and if there was radiological evidence of pulmonary infiltrates not attributable 86 to other causes. Soft tissue infection was considered to be the source of S. aureus 87 bacteremia when patients had an S. aureus culture from a tissue or a drainage specimen 88 for the affected site as well as signs of infection. Surgical wound infection was defined 89 according to the definition of the Centers for Disease Control and Prevention (4). 90
McCabe classification, which was performed by a clinician (S. Lee), was used to 91 determine the severity of underlying illness. High-burden disease was defined as MSSA 92 bacteremia that accompanied endocarditis, unremovable vascular graft infection, 93 osteomyelitis, pneumonia, deep-seated abscess, or metastatic infection (10). 94
Treatment failure was defined as 1) switching antibiotics due to the clinician's opinion 95 that treatment had failed (i.e. a lack of improvement of the clinical symptoms and signs, 96 persistence of bacteremia, or the development of metastatic infections during treatment), 97 Logistic regression was used to model the probability of treatment with nafcillin based 106 on risk factors reported by previous studies: age, McCabe classification, high burden 107 disease, site of infection, and focus eradication (6). The predicted probability of the 108 model was used as the propensity score for each patient. For the propensity score-109 matched case-control study, patients in the cefazolin treatment group were matched with 110 patients in the nafcillin treatment group who had the closest propensity scores. We 111 excluded 8 cases in which the propensity score difference was more than 0.01. (aOR 6.0; 95% CI, 1.5-23.7; P = 0.02) were significantly associated with treatment 140 failure. After adjustment for these variables, cefazolin treatment was not associated with 141 treatment failure at 4 weeks (aOR 1.2; 95% CI, 0.3-4.5; P = 0.76). The results at 12 142 weeks were similar to those at 4 weeks ( Table 2) . 143
Propensity score-matched case-control study. Forty-one patients in the cefazolin-144 treatment group were matched with the 41 patients in the nafcillin-treatment group with 145 the closest propensity scores. The clinical characteristics and demographic data of the 146 patients were comparable in the matched groups (Table 3) Treatment failure rate at 12 weeks was 15% (6/41) in the cefazolin-treatment group and 153 1 2 (P = 0.22). There was no significant difference between the matched groups in terms of 156 4-week mortality (4% vs. 4%, P > 0.99). In four patients in the cefazolin-treatment 157 group, the antibiotic agent was changed due to clinical failure; vancomycin replaced 158 cefazolin in three cases and nafcillin, which was imported through the Korea Orphan 159 Drug Center, was used for one case. Of these patients, clinical failure was determined 160 by a lack of improvement of the clinical symptoms and signs (n=2), persistence of 161 bacteremia (n=1), and the development of metastatic infections during treatment (n=1). 162
Cefazolin treatment was interrupted less frequently due to adverse drug events than was 163 nafcillin (0 (0%) vs. 7 (17%), P = 0.02) ( Table 4 ). Of 7 patients who discontinued 164 nafcillin due to adverse events, the adverse events were drug-induced fever (n = 4), 165 cytopenia (n = 2), and phlebitis (n = 1), and the median time to discontinuation of 166 nafcillin was 19 days (IQR, 7-24 days). Three patients experienced adverse events 167 within 2 weeks of starting nafcillin. infections, as our study demonstrated. Our study was designed to minimize this 178 selection bias. First, the cefazolin-treatment group included only patients who received 179 cefazolin during a period when nafcillin was unavailable at our institute due to problems 180 with the supplier. During this time, cefazolin was used for treating serious MSSA 181 infections except infection of the central nervous system. Second, we used propensity 182 scores to match the patients between the two groups in order to optimize the 183 comparison. nafcillin. Third, our study suggests that cefazolin is significantly more tolerable than 197 nafcillin. In our study, there were no significant adverse events that interrupted cefazolin 198 use while 17% of nafcillin-treated patients discontinued nafcillin due to adverse events. 199
This study had limitations in that some data should be interpreted with caution. 
